about
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell deathGlycoprotein analysis using protein microarrays and mass spectrometry.Prognostic biomarkers in ovarian cancer.Ovarian cancer biomarkers for molecular biosensors and translational medicine.Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.Comparison of specific ovarian tumor markers by elecsys analyzer 2010Early detection biomarkers for ovarian cancer.Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.Genetic markers for prediction of treatment outcomes in ovarian cancer.Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspectiveIs tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?Production and characterization of monoclonal antibodies against the extracellular domain of CA 125.Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer.Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer.Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.Integrated multiomic predictors for ovarian cancer survival
P2860
Q24632721-9C053E1A-4C63-4108-905C-C91A3197D1EDQ33927735-5F7AF81F-4995-4B4F-9915-68FAFACA2755Q34086636-C369E976-C1E2-4F14-A488-09110564CFF9Q34150097-FE4A0C3D-E462-4B98-B0BF-E1D784F11FBAQ34221652-AABF381B-79DC-410C-BFC5-9E259BBC4839Q35601405-387CC351-C406-4F58-94C8-625E77F32C1EQ36520143-73578920-D5CD-4655-87AD-EC02CE09D8C5Q36816028-0921EFF4-19B5-4847-B839-E74E1C91BF31Q37141531-B604262A-9CD7-405D-A855-2E092D07913FQ37393872-024D76FC-3B03-48B8-BD41-8B122F16057BQ38175815-E01CEA52-124F-4466-816B-F948FF8A517FQ38227080-F6ED7BFF-B1A4-4652-8429-E16237EADD51Q38649539-05C84A25-6B27-4059-B9C1-A56CDF83C148Q39543532-BC59FD1F-C2DE-4ADD-9D3E-919E8625C49FQ39742997-148E48AA-E0EF-4AD1-A4F8-71BFDA904700Q40397279-FD7223DF-F154-4A76-9541-588B97406B9DQ41264576-4AB73AE8-FC5D-42EF-85BF-A9C7A8FF2EAEQ41609074-99A2A955-1472-48B6-AD5D-AF0E9E17CB14Q41615733-E2471383-8566-4AD8-B251-5605AB05F964Q43421009-0A2829FF-3BC3-4952-AAFE-E2E3C5091A11Q50071610-F4ADDF9C-9FC2-4426-9719-F4B456F3EE6DQ50922678-377FBA48-153A-48C4-BBB9-3BEFE5CA32DAQ57177267-9248EDDA-86EA-472A-AF12-15C8188B8EDF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer antigen 125 and prognosis.
@en
Cancer antigen 125 and prognosis.
@nl
type
label
Cancer antigen 125 and prognosis.
@en
Cancer antigen 125 and prognosis.
@nl
prefLabel
Cancer antigen 125 and prognosis.
@en
Cancer antigen 125 and prognosis.
@nl
P1476
Cancer antigen 125 and prognosis.
@en
P2093
Estrid Høgdall
P356
10.1097/GCO.0B013E3282F2B124
P577
2008-02-01T00:00:00Z